Legend Biotech, a clinical stage CAR-T immuno-oncology biotech being spun out of GenScript, raised $424 million by offering 18.4 million ADSs at $23, above the range of $18 to $20. Legend Biotech plans to list on the Nasdaq under the symbol LEGN. Morgan Stanley, J.P. Morgan and Jefferies acted as lead managers on the deal.
